TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02478320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilorasertib
Description: 200 mg administered by mouth twice daily on Days 1, 8, and 15 of each 28-day cycle.
Study: NCT03286478

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Mindfulness-based body image intervention to be delivered 1 lesson per week for 5 weeks (5 x 45 minute lessons), by trained school teachers.
Study: NCT03962855

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifetroban Sodium
Description: Ifetroban sodium 250 mg capsule once daily for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo arm to match Ifetroban Sodium once daily for 4 weeks.
Study: NCT00565409

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: Subcutaneous (SC), 50 mg, once weekly for 88 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Oral, 15 to 25 mg (varying based on dosage the subject is receiving at the time of screening and may be increased at the discretion of the investigator through Week 28 to a maximum of 25 mg/week), once weekly for 88 weeks.~If a subject experiences an adverse event (AE) during the study, Methotrexate may be decreased by 2.5 or 5.0 mg weekly (the minimum dose to stay in the study is 10 mg/week).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: Subcutaneous (SC), 25 mg, once weekly from week 36 to week 88.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Oral, 15 to 25 mg (varying based on dosage the subject is receiving at the time of screening and may be increased at the discretion of the investigator through Week 28 to a maximum of 25 mg/week), once weekly for 88 weeks.~If a subject experiences an adverse event (AE) during the study, Methotrexate may be decreased by 2.5 or 5.0 mg weekly (the minimum dose to stay in the study is 10 mg/week).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous (SC), once weekly from week 36 to week 88.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Oral, 15 to 25 mg (varying based on dosage the subject is receiving at the time of screening and may be increased at the discretion of the investigator through Week 28 to a maximum of 25 mg/week), once weekly for 88 weeks.~If a subject experiences an adverse event (AE) during the study, Methotrexate may be decreased by 2.5 or 5.0 mg weekly (the minimum dose to stay in the study is 10 mg/week).
Study: NCT04548206

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates training
Description: The program consisted of core-based Pilates exercises on the mat for 60 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: The program consisted of progressive relaxation exercises at home.
Study: NCT04306328

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurostimulation
Description: Implantation of 2 multicontact cuff electrodes in the upper limb of patients with tetraplegia and control of the stimulation by contralateral shoulder movements
Study: NCT02249403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talsaclidine 6 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talsaclidine 12 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talsaclidine 24 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talsaclidine 36 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talsaclidine 36 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03286478

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dissonance
Description: Dissonance-based body image intervention to be delivered 1 lesson per week for 5 weeks (5 x 45 minute lessons), by trained school teachers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dove Confident Me
Description: Dove Confident Me body image intervention to be delivered 1 lesson per week for 5 weeks (5 x 45 minute lessons), by trained school teachers.
Study: NCT03701217

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eltrombopag
Description: Eltrombopag 25mg bid, starts from the day when platelet count decreases lower than 30×10'9/L, and the treatment lasts for at least 5 days, and stops until platelet count goes up to more than 30×10'9/L, after consolidation therapy in AML patents.
Study: NCT02239107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl cysteine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic ovarian drilling

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic ovarian drilling
Study: NCT01726374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEP(500)
Description: One cycle of BEP(500):~Etoposide 165 mg/m2 IV infusion - days 1, 2, 3 Cisplatin 50 mg/m2 IV infusion - days 1, 2 Bleomycin 30,000 IU IV infusion - days 1 (or 2), 8, 15
Study: NCT02160015

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrocardiogram
Description: Undergo ECG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT00382174

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical administration of 0.00% thymosin beta 4 qd up to 84 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymosin Beta 4
Description: Topical Administration of 0.01, 0.02, and 0.1% thymosin beta 4 gel qd for up to 84 days
Study: NCT04255914

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal plastic surgery procedure and orthodontic treatment
Description: subepithelial connective tissue graft and orthodontic tooth levelling and alignment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal plastic surgery procedure
Description: subepithelial connective tissue graft procedure
Study: NCT01732614

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Topcon Endpoint Management laser
Study: NCT03515161

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: closed-loop
Description: Vasopressor admnistration in the closed loop group will be performed via a closed loop (automated) system that will use an infusion pump (Q-Core) and a controller (a computer run index and algorithm developed by Sironis) to make frequent, regular and accurate adjustments to the amount of vasopressor the patient receives using feedback from standard operating room monitors.
Study: NCT03512093

Intervention type: OTHER
Intervention: Retrospective chart review
Description: A retrospective chart review of preterm neonates born in one of the birthing SMRU unit between January 2008 and December 2017 and for whom a medical chart is available. In addition we propose to analyze the growth trajectory, the prevalence of anemia (Hct \< 33%) and the level of neurodevelopment achieved in the first year of life reported in the clinical charts of preterm neonates born \< 34+0 weeks of gestation.

Intervention type: OTHER
Intervention: Focus Group Discussion (FGD) of the medical staff
Description: Focus Group Discussion (FGD) of the medical staff working in the SCBU firstly on the benefits and difficulties in using existing guidelines for preterm care and secondly on the feasibility and acceptability of changes in the guidelines 3-6 months after their implementation.
Study: NCT04888468

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pCAR-19B cells
Description: Drug: pCAR-19B cells； Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
Study: NCT03701217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Eltrombopag 25mg bid, starts from the day when platelet count decreases lower than 30×10'9/L, and the treatment lasts for at least 5 days, and stops until platelet count goes up to more than 30×10'9/L, after consolidation therapy in AML patents.
Study: NCT03570437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib tablets, 300 mg twice-daily
Study: NCT03512093

Intervention type: OTHER
Intervention: Interviews of mothers
Description: Interviews of mothers who delivered preterm neonates (\< 37+0 weeks of gestation) to understand the challenges they faced while caring for their child.
Study: NCT01044654

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SB-728-T
Description: Each infusion will be 5-30 billion ZFN modified CD4+ T-cells

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SB-728-T
Description: Each infusion will be 5-30 billion ZFN modified CD4+ T-cells

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SB-728-T
Description: Each infusion will be 5-30 billion ZFN modified CD4+ T-cells

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SB-728-T
Description: Each infusion will be 5-30 billion ZFN modified CD4+ T-cells

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SB-728-T
Description: Each infusion will be 5-30 billion ZFN modified CD4+ T-cells
Study: NCT01112813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: 0.4-0.8 mmol/L for 2 months
Study: NCT04511221

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animals subsp. lactis BL04+PreforPro
Description: One 15mg capsule taken orally each day
Study: NCT01185561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention
Description: The intervention is group therapy for depression treatment based on cognitive behavioral therapy principles developed for women with type 2 diabetes. Specifically, the intervention comprises activities including (1) Education about how dysphoric symptoms (i.e., depressive symptoms, anxiety, and anger) affect glycemic control; (2) Recognition of dysphoric symptoms; and (3) Management of dysphoric symptoms using cognitive-behavioral skills.
Study: NCT04556539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC10914
Description: 400mg TID, oral admination on fasting condition
Study: NCT00105807

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: participation in low intensity exercise

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: participation in art and music activities
Study: NCT05200455

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microelectrodes
Description: Microelectrode implantation
Study: NCT02812914

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-cost gas stove
Description: Women will be provided with a 3-burner liquid propane gas stove and one year's supply of gas

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-cost gas stove
Description: Women will be provided with a 3-burner liquid propane gas stove and one year's supply of gas

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer education classes
Description: Women will participate in four classes on how to safely use gas stoves and methods to reduce exposure to air pollution

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resource-intensive behavioral intervention approach
Description: Women will participate in four classes on how to safely use gas stoves and methods to reduce exposure to air pollution. Additionally, peer educators will visit each home after group classes to help the woman, and key decision-makers in her family, identify top priority strategies to reduce air pollution. Using a checklist, peer educators will observe whether household members are adhering to tailored strategies at subsequent home visits, and provide ongoing support to women and their families.
Study: NCT04786054

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: BED Questionnaire
Description: BED Questionnaire
Study: NCT04364087

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral glucose tolerance test
Description: Oral glucose tolerance test with 75 g glucose (75 g OGTT) will be performed to those with normal fasting glucose and HbA1C levels. Women will be recommended to have normal diet for 3 days and overnight fasting for at least 8 hours. The blood withdrawal will be performed twice: (i) fasting and (2i) 2 hours after solution administration. The volume of blood for each test is 2 ml. Impaired glucose tolerance will be diagnosed when two-hour glucose levels of 140 to 199 mg/dL (7.8 to 11.0 mmol/l) (American Diabetes Association, 2018).
Study: NCT01912573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal (IN) naloxone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous (IV) naloxone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular (IM) naloxone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intraosseus (IO) naloxone
Study: NCT00233532

Intervention type: DRUG
Group type: OTHER
Intervention: Trandolapril
Description: 0.5, 1,2,4mg/once daily/ for 26 weeks (If BP was not controlled, dose was escalated to the next higher dosage every 4-5 weeks).

Intervention type: DRUG
Group type: OTHER
Intervention: Trandolapril
Description: 0.5, 1,2,4mg/once daily/ for 26 weeks (If BP was not controlled, dose was escalated to the next higher dosage every 4-5 weeks).

Intervention type: DRUG
Group type: OTHER
Intervention: Trandolapril
Description: 0.5, 1,2,4mg/once daily/ for 26 weeks (If BP was not controlled, dose was escalated to the next higher dosage every 4-5 weeks).
Study: NCT03151031

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: The cooling procedure for the knee joint will be initiated by using a cryopack or cold-pack. On completion of the initial SEBT, the participant will lie supine and the investigator will apply the cryotherapy for 10 minutes. After the 10 minute period of cryotherapy, the cryopack will be removed, and the participants will perform SEBT for the second time.
Study: NCT02230189

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Segmental airway allergen challenge

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Methacholine challenge test

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Spirometry

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Allergen skin prick test
Study: NCT02814058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolpidem hemitartarate 1.75 mg - Sequency 1
Description: zolpidem hemitartarate 1.75 mg in fasting (period 1) and zolpidem hemitartarate 1.75 mg postprandial (period 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolpidem hemitartarate 1.75 mg - Sequency 2
Description: zolpidem hemitartarate 1.75 mg postprandial (period 1) and zolpidem hemitartarate 1.75 mg in fasting (period 2)
Study: NCT02832414

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive weight loss program
Description: behavioral and dietary supplement
Study: NCT02828384

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low fodmap diet
Description: dietary teaching

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Psyllium
Description: 7.1g of psyllium daily
Study: NCT02058979

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BOLUS INFUSION (Ancef)
Description: Bolus Infusion of antibiotics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CONTINUOUS INFUSION (Ancef)
Description: Continuous Infusion of ANCEF with infusion pump
Study: NCT03627052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: In the double-blind period, itacitinib administered orally once or twice daily at the protocol-defined dose according to treatment group randomization. In the open-label extension, itacitinib administered at doses determined from the double-blind period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally twice daily in the double-blind period.
Study: NCT02917005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: CDK 4/6 inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Aromatase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Aromatase inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin
Description: LHRH agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: LHRH agonist
Study: NCT03753022

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Group G5
Description: Submitted to peep 5

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group G10
Description: Submitted to peep 10

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group G15
Description: Submitted to peep 15
Study: NCT04335071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Description: Patients get one dose (= 8 mg/kg bodyweight, max. single dose 800 mg) Actemra® (active ingredient: TCZ) intravenously in 100 mL NaCl 0.9% after confirmation of progressive dyspnoea. Infusion time: 60 min. The procedure is repeated once if no clinical improvement in the 8-point WHO scale is observed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo-controlled intervention is one dose (100 mL) NaCl 0.9% intravenously administered after confirmation of progressive dyspnoea. Infusion time: 60 min. The procedure is repeated once if no clinical improvement in the 8-point WHO scale is observed.
Study: NCT04163939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vista Therapy Collar
Description: The patient will wear the cervical collar

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patient will not wear the cervical collar
Study: NCT01228214

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 5mg/daily for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amiloride
Description: 5mg/daily for 12 months
Study: NCT04414293

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Lung Low Dose Radiation
Description: The administration of low-dose lung radiation produces anti-inflammatory effects that will decrease the pulmonary inflammatory response.
Study: NCT01305187

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid Filler
Description: The dosage is individualized depending on the depth of the NLF. The goal is to achieve optimal correction of both NLF with single implantations of Belotero® Basic and Juvéderm® Ultra 3 respectively. Each subject will be injected with Belotero® Basic and Lidocaine containing Juvéderm® Ultra 3 according to a split-face design. The allocation of fillers to the side of the face will be randomized. The randomization method is block-wise with a ratio 1:1 to the groups Belotero® Basic left and Juvéderm® Ultra 3 right, Belotero® Basic right and Juvéderm® Ultra 3 left.
Study: NCT02985411

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Gardening Intervention
Description: Provided with supplies to plan/plant 3 vegetable gardens over the course of a year. Survivors will be paired with a master gardener from their local Cooperative Extension to help guide them and provide mentorship in vegetable gardening,

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Gardening Intervention
Description: Subjects will be monitored for 1-year and will then receive the same vegetable gardening intervention as described under the Immediate Gardening Intervention
Study: NCT02553187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kanglaite Injection
Description: 200 mL, slow IV drip, once daily for 14 consecutive days, subsequent courses repeated after a 7-day interval.~Subjects will be treated for 4 courses (12 weeks).
Study: NCT00920556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5.0g SRT501
Description: 5.0g SRT501 will be supplied in clinical kits as a powder which will be reconstituted with vehicle and water into a liquid suspension. SRT501 will be administered orally as a liquid suspension for 20 consecutive days in each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib (1.3 mg/m2) will be given as an intravenous solution in a 3-5 second push on Day 1, 4, 8 and 11 in every 21 day cycle.
Study: NCT01193101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: LCZ696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: LCZ696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: LCZ696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo to LCZ696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo to LCZ696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo to LCZ696

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo to LCZ696
Study: NCT02752347

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surface EMG device
Description: measuring the muscles activity using surface EMG device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surface EMG device
Description: measuring the muscles activity using surface EMG device
Study: NCT02982330

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Carbohydrate Breakfast
Description: A low carbohydrate breakfast containing \<10% carbohydrate, \~75% fat, and 15% protein. Matched for calories to the active comparator arm.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Carbohydrate Breakfast
Description: A low carbohydrate breakfast containing \<10% carbohydrate, \~75% fat, and 15% protein. Matched for calories to the active comparator arm.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guidelines Breakfast
Description: A low fat breakfast containing \~55% carbohydrate, \<30% fat, and 15% protein. Matched for calories to the experimental arm.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guidelines Breakfast
Description: A low fat breakfast containing \~55% carbohydrate, \<30% fat, and 15% protein. Matched for calories to the experimental arm.